Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Doctor Care Anywhere Group PLC (DOC.AX)
London, GB
Doctor Care Anywhere Group PLC, together with its subsidiaries, provides digital healthcare and development services in the United Kingdom and the Republic of Ireland. It offers services in the areas of medical letters, imaging support, blood testing, and mental health support, as well as comprehensive health assessments, health solutions, specialist care pathways, physiotherapy support, and GP and ACP appointments. The company provides treatments for allergies, intolerances, colds, flu, minor illnesses, gut health, joint, muscles, lifestyle support, men’s and women’s health, mental health, sexual health, and skin conditions. Doctor Care Anywhere Group PLC was founded in 2013 and is headquartered in Mayfair, the United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -27.03% | +3.85% | -12.90% | +28.57% | +175.51% | -86.89% | -85.48% | -85.48% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | +1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%-2.3% Q4'25: -1.7% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%+114.0% ★ Q4'25: +117.9% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+8.7% Q4'25: +15.6% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+4.5% Q4'25: +5.1% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%+34.3% ★ Q4'25: +80.2% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+31.7% Q4'25: +0.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×2.47× Q4'25: 1.14× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11.57M
est: 11.57M (+0.0%)
|
24.97M
est: 23.02M (+8.5%)
|
29.31M
est: 30.38M (-3.5%)
|
38.46M
est: 43.16M (-10.9%)
|
39.33M
est: 40.78M (-3.5%)
|
38.43M
est: 39.07M (-1.6%)
|
39.75M
39.75M – 39.75M
+1.7% YoY
|
44.49M
44.49M – 44.49M
+11.9% YoY
|
48.02M
48.02M – 48.02M
+7.9% YoY
|
| EBITDA |
-13.38M
est: -5.88M (-127.6%)
|
-18.92M
est: -11.70M (-61.8%)
|
-16.95M
est: -15.44M (-9.8%)
|
-5.78M
est: -21.94M (+73.7%)
|
-2.15M
est: 25.75M (-108.3%)
|
4.21M
est: 24.67M (-82.9%)
|
25.10M
25.10M – 25.10M
+1.7% YoY
|
28.09M
28.09M – 28.09M
+11.9% YoY
|
30.32M
30.32M – 30.32M
+7.9% YoY
|
| EBIT |
-14.03M
est: -6.43M (-118.1%)
|
-20.39M
est: -12.80M (-59.3%)
|
-18.78M
est: -16.89M (-11.2%)
|
-8.17M
est: -24.00M (+66.0%)
|
-4.45M
est: 23.89M (-118.6%)
|
1.73M
est: 22.89M (-92.4%)
|
23.29M
23.29M – 23.29M
+1.7% YoY
|
26.06M
26.06M – 26.06M
+11.9% YoY
|
28.13M
28.13M – 28.13M
+7.9% YoY
|
| Net Income |
-31.28M
est: -15.06M (-107.7%)
|
-20.22M
est: -19.01M (-6.3%)
|
-22.03M
est: -11.52M (-91.3%)
|
-10.05M
est: -10.79M (+6.8%)
|
-6.29M
est: -3.31M (-90.0%)
|
1.17M
est: 1.66M (-29.4%)
|
1.92M
1.92M – 1.92M
+16.2% YoY
|
3.08M
3.08M – 3.08M
+60.0% YoY
|
4.23M
4.23M – 4.23M
+37.5% YoY
|
| SGA |
10.27M
est: 7.84M (+31.1%)
|
14.23M
est: 15.59M (-8.7%)
|
25.64M
est: 20.57M (+24.6%)
|
23.07M
est: 29.23M (-21.1%)
|
17.86M
est: 22.20M (-19.6%)
|
8.60M
est: 21.27M (-59.6%)
|
21.64M
21.64M – 21.64M
+1.7% YoY
|
24.22M
24.22M – 24.22M
+11.9% YoY
|
26.14M
26.14M – 26.14M
+7.9% YoY
|
| EPS |
-0.18
est: -0.05 (-275.9%)
|
-0.06
est: -0.06 (-3.7%)
|
-0.06
est: -0.04 (-66.9%)
|
-0.02
est: -0.03 (+35.0%)
|
-0.02
est: -0.01 (-103.9%)
|
0.00
est: 0.00 (-22.4%)
|
0.00
0.00 – 0.00
+16.2% YoY
|
0.01
0.01 – 0.01
+60.0% YoY
|
0.01
0.01 – 0.01
+37.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-01 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Laura O'Riordan | Chief Executive Officer & Director | 911.7K | female |
| Niall Dore | Interim Chief Financial Officer | 326.1K | male |
| David J. Walker | Chief Commercial Officer | — | male |
| Jamie Aspinall | Chief of Staff | — | male |
| Kristien Bateman | Chief Operating Officer | — | male |
| Maaya Chaplin | Head of Marketing | — | female |
| Andrew Bellingham | Chief Product & Proposition Officer | — | male |
| Zoe Sullivan | Chief Customer Officer | — | female |
| Anushka Mehrotra | Chief Medical Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DOC.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
